Han In Pharmaceutical

Hanin Pharmaceutical is a leading South Korean pharmaceutical company specializing in the development and manufacturing of treatments for Central Nervous System (CNS) disorders. Established in 1978, the company has secured a dominant market position in psychiatry and neurology, offering a comprehensive portfolio of drugs for schizophrenia, depression, dementia, and epilepsy. Beyond its CNS core, Hanin produces a variety of medications for circulatory, digestive, and respiratory conditions. The company operates a dedicated research institute focused on formulation technology and the development of both generic and innovative new drugs. Hanin is publicly traded on the Korea Exchange and maintains GMP-certified manufacturing facilities to support its domestic and international operations.